CVRx, Inc. (CVRX) AI Stock Analysis

Founded in 2000 and based in Minneapolis, Minnesota, CVRx, Inc. is a medical device company developing neuromodulation therapies for cardiovascular diseases. Its flagship product, Barostim, is designed for patients suffering from heart failure with reduced ejection fraction or systolic heart failure. Barostim activates the body's natural cardiovascular reflexes through neuromodulation to improve cardiac function and relieve symptoms. CVRx commercializes its technology via direct sales forces, independent distributors, and sales agents across the United States, Germany, Europe, and other international regions, while continuing research and development initiatives to expand its product line.

CVRx expanded annual revenue from $13.0M in FY2021 to $56.7M in FY2025, recording a 5-year revenue CAGR of 56.4% from FY2020 to FY2025. Revenue growth moderated from 115.4% in FY2021 to 10.4% in FY2025. Gross margin improved over the same period, rising from 72.1% in FY2021 to 85.3% in FY2025. Despite revenue expansion, the company has operated at consistent losses, posting net income of -$53.3M in FY2025 compared to -$43.1M in FY2021. In the trailing twelve months, revenue reached $61.2M with an operating margin of -82.9%. For the latest quarter ended June 30, 2026, year-over-year quarterly revenue growth was 15.6%.

As of June 30, 2026, CVRx held $64.6M in cash and short-term investments against total debt of $59.4M, resulting in net cash of $5.2M. Total assets stood at $92.3M, and shareholders' equity was $20.0M, supporting a current ratio of 8.04 and a debt-to-equity ratio of 2.98. In FY2025, operating cash flow was -$40.2M and capital expenditures were $580,000, yielding free cash flow of -$40.8M. Over 5 years, the company's share count increased by 30.2%.

CVRx has a market cap of $34.6M and an enterprise value of $67.3M. The stock trades at a price-to-sales multiple of 0.6x and an enterprise value to revenue multiple of 1.1x, well below the median of its US-listed Healthcare peers, which trade at a price-to-sales multiple of 4.1x. Its price-to-book ratio is 3.6x. Over the past year, CVRX fell 86.3%, while the S&P 500 gained 16.8%. Over a 5-year period, the stock declined 91.7% compared to an 83.0% gain for the benchmark.

Wall Street analysts maintain 3 Strong Buy, 3 Hold, and 1 Sell ratings on CVRx. The mean price target is $4.58, representing an upside of 252.6% over the last close of $1.30 on October 16, 2026. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $58.9M and an EPS of -$2.02. For the next fiscal year, 7 analysts project revenue of $66.2M and an EPS of -$1.88. CVRx beat EPS estimates in 1 of the last 4 quarters, with next earnings scheduled for November 4, 2026.

This page is an AI-written research summary of CVRx, Inc. (CVRX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CVRX income statement, CVRX balance sheet, CVRX key metrics, CVRX analyst forecast, CVRX chart. See the CVRX stock overview for the latest quote and news.